For research use only. Not for therapeutic Use.
Sotagliflozin（Cat No.:I000136）is a dual inhibitor of sodium-glucose co-transporter 1 (SGLT1) and sodium-glucose co-transporter 2 (SGLT2), designed to improve glycemic control in patients with type 1 and type 2 diabetes. By inhibiting SGLT2 in the kidneys, it reduces glucose reabsorption and increases urinary glucose excretion. Additionally, its inhibition of SGLT1 in the gastrointestinal tract delays glucose absorption, further lowering postprandial blood glucose levels. Sotagliflozin’s dual mechanism offers comprehensive glucose management and has shown potential to reduce cardiovascular risks, making it an innovative option for diabetes treatment.
| Catalog Number | I000136 |
| CAS Number | 1018899-04-1 |
| Synonyms | (2S,3R,4R,5S,6R)-2-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-6-methylsulfanyloxane-3,4,5-triol |
| Molecular Formula | C21H25ClO5S |
| Purity | 98% |
| Target | SGLT2 |
| Target Protein | |
| Appearance | Solid |
| Storage | Dry, dark and at 2 - 8 °C for six months or -20°C for two years. |
| IC50 | SGLT2 IC50: 1.8 nM |
| IUPAC Name | (2S,3R,4R,5S,6R)-2-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-6-methylsulfanyloxane-3,4,5-triol |
| InChI | InChI=1S/C21H25ClO5S/c1-3-26-15-7-4-12(5-8-15)10-14-11-13(6-9-16(14)22)20-18(24)17(23)19(25)21(27-20)28-2/h4-9,11,17-21,23-25H,3,10H2,1-2H3/t17-,18-,19+,20+,21-/m1/s1 |
| InChIKey | QKDRXGFQVGOQKS-CRSSMBPESA-N |
| SMILES | CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)SC)O)O)O)Cl |
| Reference | [1]. Zambrowicz B, et al. LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clin Pharmacol Ther. 2012 Aug;92(2):158-69. [2]. Powell DR, et al. LX4211 increases serum glucagon-like peptide 1 and peptide YY levels by reducing sodium/glucose cotransporter 1 (SGLT1)-mediated absorption of intestinal glucose. J Pharmacol Exp Ther. 2013 May;345(2):250-9. |
